Brean Murray Initiates Coverage on Molecular Insight Pharmaceuticals (MIPI) with a Buy
MIPI Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 25 | Down: 12 | New: 36
Brean Murray initiates coverage on Molecular Insight Pharmaceuticals (Nasdaq: MIPI) with a Buy. Price target $11.
To see more analyst ratings on MIPI Click Here.
Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States.
To see more analyst ratings on MIPI Click Here.
Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States.
You May Also Be Interested In
- UPDATE: Canaccord Genuity Starts KIT Digital (KITD) at Hold; OTT Video Trends Remain Strong, But Concerns Remain
- UBS Raises Price Target and EPS Estimate on LyondellBasell Industries (LYB); Use Dip As Buying Opportunity
- Roth Capital Starts Celsion Corp (CLSN) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
